All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.  View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Encouraging interim phase I data for FT516 and FT538 cellular products to treat R/R AML

By Maria Kasimati

Share:

May 18, 2021


FT516 and FT538 are two induced pluripotent stem cell (iPSC)-derived cell therapies currently under investigation in phase I clinical trials for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML). FT516 is an off-the-shelf natural killer cell immunotherapy administered as monotherapy. FT538 is the first CRISPR-edited iPSC-derived therapy, and its investigational new drug (IND) application has recently been cleared by the U.S. Food and Drug Administration (FDA) as a new monotherapy for patients with AML and as a combination therapy with daratumumab for the treatment of multiple myeloma.

Recently, an update with a cutoff date of April 16, 2021, on two phase I dose-escalation studies evaluating FT516 and FT538 as monotherapies to treat patients with R/R AML was published.1

The ongoing phase I dose-escalation study of FT516 resulted in:

  • three complete remissions with incomplete hematologic recovery, including one study subject that successfully proceeded to allogeneic stem cell transplantation; and
  • one morphologic leukemia-free state.

For the FT538 study, three patients were enrolled in the first dose cohort of 100 million cells per dose. The results achieved included:

  • one complete remission with incomplete hematologic recovery.

Across these studies, an objective response with complete leukemic blast clearance in the bone marrow was achieved for five of the twelve patients enrolled.

In both trials there were no cases of dose-limiting toxicity, cytokine release syndrome (any grade), immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease. Overall, the interim data suggest that these novel monotherapies could potentially help patients with R/R AML to achieve durable remissions and complete leukemic blast clearance without further therapeutic interventions and with limited side effects.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

Your opinion matters

What barriers do you encounter when conducting multiple MRD tests during treatment?